What are Ocular Hypertension and Glaucoma?
Ocular Hypertension is when the pressure inside the eye, also known as intraocular pressure or IOP, is higher than normal. In people with Ocular Hypertension, the optic nerve appears normal and without damage. Glaucoma is an eye disease in which pressure within your eyes becomes too high and causes damage to your optic nerve. This damage is irreversible and can lead to blindness in advanced cases. It affects more than two million people over the age of 40 in the United States alone.

How do I know if I have Ocular Hypertension or Glaucoma?
If you have Ocular Hypertension (increased eye pressure without nerve damage) it can lead to Glaucoma. Glaucoma can develop slowly and you may not be aware of the gradual loss of sight until late in the disease when your vision has been affected.

What kinds of treatments are available for Ocular Hypertension and Glaucoma?
Glaucoma cannot be cured, but it can be successfully controlled in most cases with laser therapy, surgery, or topical medication(s) such as eye drops. The most common treatment for Ocular Hypertension and Glaucoma is the use of medicated eye drops.

Travoprost Intracanalicular Depot (OTX-TP)
Doctors are now evaluating, in a placebo-controlled study, a new investigational drug loaded intracanalicular depot (OTX-TP), more commonly known as a punctum plug, for use in the treatment of Glaucoma or Ocular Hypertension in place of medicated eye drops. OTX-TP may deliver a constant dose of Travoprost, which is a commonly used topical medication that can help reduce the pressure within the eye. This may allow you to receive a steady dose of the therapy for the desired duration of therapy. Once placed in the eye, the intracanalicular depot will begin to soften and break down over time while delivering medication, and then eventually wash away with your tears.

OTX-TP Clinical Study
Your eye doctor is currently taking part in a clinical research study to further evaluate the safety and performance of OTX-TP. OTX-TP is an investigational drug which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

If you or anyone you know is interested in participating, please contact your eye doctor to see if you qualify. Some of the criteria that must be met are listed below:

- You must be at least 18 years old
- You must be diagnosed with ocular hypertension or open-angle glaucoma and considered stable for at least 2 months
- You must be willing to comply with all medication restrictions
- You must not be participating in any other studies
- You must be able to comply with the follow-up visit schedule (10-12 follow-up visits during a 12 week period); however, additional visits may be required.

During these visits, your doctor will evaluate your progress. You will be compensated for your time, travel, and participation in the study.